Intercurrent infection predicts mortality in patients with late hepatic artery thrombosis listed for liver retransplantation.

Autor: Leithead JA; Liver Unit, Queen Elizabeth Hospital, Birmingham, United Kingdom; National Institute for Health Research Biomedical Research Unit and Centre for Liver Research, University of Birmingham, Birmingham, United Kingdom. j.a.leithead@bham.ac.uk, Smith MR, Materacki LB, Sagar VM, Gunson BK, Bramhall SR, Mutimer DJ, Shah T
Jazyk: angličtina
Zdroj: Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society [Liver Transpl] 2012 Nov; Vol. 18 (11), pp. 1353-60. Date of Electronic Publication: 2012 Sep 26.
DOI: 10.1002/lt.23518
Abstrakt: Liver retransplantation for late hepatic artery thrombosis (HAT) is considered the treatment of choice for select patients. Nevertheless, there is a paucity of data to aid decision making in this setting. The aims of this single-center study of patients listed for late HAT were (1) to determine variables associated with wait-list mortality, (2) to describe survival after retransplantation, and (3) to determine variables associated with mortality after retransplantation. Seventy-eight patients were diagnosed with late HAT (incidence = 3.9%). Of the 49 patients listed for retransplantation, 9 died on the waiting list and 36 were retransplanted. The estimated 1-year survival after listing for retransplantation was 53.7%. Only multidrug-resistant (MDR) bacteria-positive cultures were predictive of wait-list mortality (P = 0.01). After retransplantation, the estimated 1- and 5-year patient survival was 71.9% and 62.5%, respectively. Increasing Model for End-Stage Liver Disease score (overall P = 0.007), MDR bacteria-positive cultures (P = 0.047), and continued antibiotic therapy (P = 0.001) at the time of retransplantation were risk factors for post retransplant death. In conclusion, patients who undergo liver retransplantation for late HAT have satisfactory outcomes. However, the presence of active infection and MDR bacteria-positive cultures should be taken into account when risk stratifying such patients.
(Copyright © 2012 American Association for the Study of Liver Diseases.)
Databáze: MEDLINE
Externí odkaz: